SEC Form 4	
------------	--

Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
as Caption 20(b) of the Investment Company (Act of 1040

		of Section So(ii) of the investment Company Act of 1940										
1. Name and Address of I <u>Robb Gary Charl</u> (Last) (First C/O CORCEPT THE	tes (Middle)	2. Issuer Name and Ticker or Trading Symbol <u>CORCEPT THERAPEUTICS INC</u> [CORT] 3. Date of Earliest Transaction (Month/Day/Year) 09/01/2023	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below) Chief Business Officer									
INCORPORATED 149 COMMONWEA (Street)		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person									
MENLO PARK CA (City) (Sta		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to satisfy the affirmative defense conditions of Rule 10b5-1(c). See the satisfy the affirmative defense conditions of Rule 10b5-1(c). See the satisfy the affirmative defense conditions of Rule 10b5-1(c). See the satisfy the affirmative defense conditions of Rule 10b5-1(c).										
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	09/01/2023		A		500 ⁽¹⁾	A	\$33.1 ⁽²⁾	20,529 ⁽³⁾	D	
Common Stock	09/01/2023		A		500 ⁽⁴⁾	A	\$0.00	21,029 ⁽³⁾	D	
Common Stock								8,061	I	Custodial Account for Child ⁽⁵⁾
Common Stock								8,061	I	Custodial Account for Child ⁽⁵⁾
Common Stock								8,061	I	Custodial Account for Child ⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/\	and 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form:	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2023.

2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

3. Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the oneyear anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

5. These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

(s/ Joseph Douglas Lyon, as attorney-in-fact for Gary Charles Robb.
** Signature of Reporting Person

09/06/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.